Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: An update. Part II: Clinical studies with leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma

Pharmacological Research

Volumn 40, Issue 1, 1999, Pages 15-29

  Devillier, Philippe ^a   Baccard, Nathalie ^a   Advenier, Charles ^b  

^a Ho a5pital Maison Blanche Ctr H   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Asthma; Glucocorticoids; Leukotriene receptor antagonists; Leukotriene synthesis inhibitors; Leukotrienes

Indexed keywords

1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 2 [4 [2 (5 TETRAZOLYLMETHYL)BENZYLOXY]PHENOXYMETHYL]QUINOLINE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 5 [2 (2 CARBOXYETHYL) 3 [6 (4 METHOXYPHENYL) 5 HEXENYLOXY]PHENOXY]VALERIC ACID; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; ACETYLSALICYLIC ACID; ANTIASTHMATIC AGENT; ATRELEUTON; CINALUKAST; CORTICOSTEROID; HISTAMINE H1 RECEPTOR ANTAGONIST; IRALUKAST; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEUKOTRIENE SYNTHESIS INHIBITOR; MONTELUKAST; MOXILUBANT MALEATE; PEPTIDOLEUKOTRIENE; POBILUKAST; PRANLUKAST; QUIFLAPON; SULUKAST; TOMELUKAST; UNCLASSIFIED DRUG; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; DRUG SAFETY; EXERCISE; HUMAN; LUNG FUNCTION; PATHOGENESIS; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

EID: 0032979807     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0461     Document Type: Article

References (143)

1. Brooks C DW, Summers J B. Modulators of leukotriene biosynthesis and receptor activation. J Med Chem. 39:1996;2629-2654.
2. 4receptor antagonists: recent clinical developments. Exp Opin Invest Drugs. 5:1996;73-77.
3. Thorax. 51:1996;1178-1184.
4. 4antagonists in antiasthma trials: early promise for a single mediator antagonist. Pulm Pharmacol. 5:1992;77-80.
5. 4induced bronchoconstriction in man. Br J Clin Pharmacol. 25:1988.
6. 4-induced bronchoconstriction in normal man. J Allergy Clin Immunol. 79:1987;816-821.
7. 4-induced bronchoconstriction by p.o. J Pharmacol Exp Ther. 246:1988;732-738.
8. 4in atopic subjects. J Allergy Clin Immunol. 83:1989;939-944.
9. Capra V, Bolla M, Belloni P A, Mezzetti M, Folco G C, Nicosia S, Rovati G E. Pharmacological characterization of the cysteinyl-leukotriene receptor antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. Br J Pharmacol. 123:1998;590-598.
10. 4receptor antagonist ICI-204,219. Am Rev Respir Dis. 141:1990;988-992.
11. Smith L J, Glass M, Minkwitz M L. Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI-204,219. Clin Pharmacol Ther. 54:1993;430-436.
12. 4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther. 61:1997;83-92.
13. 4challenge in normal volunteers. Thorax. 52:1997;519-522.
14. Wensing G, Heinig R, Kuhlmann J. Pharmacodynamics and pharmacokinetics of BAYx7195 aerosol, a new and selective receptor antagonist of cysteinyl leukotrienes, in normal volunteers. Br J Clin Pharmacol. 42:1996;171-178.
15. 4-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol. 88:1991;193-198.
16. Sirois P, Borgeat P, Lauziere M, Dubé L, Rubin P R, Kesterson J. Effect of zileuton (A-64077) on the 5-lipoxygenase activity of human whole blood ex vivo. Agents Actions. 34:1991;117-120.
17. Clin Pharmacol Ther. 56:1994;22-30.
18. Barnes N C, Kuitert L. Influence of leukotriene antagonists on baselin e pulmonary function and asthmatic responses. Adv Prostaglandin Thromboxane Leukot Res. 22:1994;217-226.
19. Hui K P, Barnes N C. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet. 337:1991;1062-1063.
20. Reiss T F, Sorkness C A, Stricker W, Botto A, Busse W W, Kundu S, Zhang J. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with or without inhaled corticosteroids. Thorax. 52:1997;45-48.
21. Chest. 111:1997.
22. 4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis. 146:1992;358-363.
23. 4antagonist, MK-679. Am Rev Respir Dis. 147:1993;1442-1446.
24. 4receptor antagonist. New Engl J Med. 323:1990;1736-1739.
25. Bronsky E A, Kemp J P, Zhang J, Guerreiro D, Reiss T F. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther. 62:1997;556-561.
26. Leff J A, Busse W W, Pearlman D, Bronsky E A, Kemp J, Hendeles L, Dockhorn R, Kundu S, Zhang J, Seidenberg B C, Reiss T F. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 339:1998;147-152.
27. Adkins J C, Brogden R N. Zafirlukast. Drugs. 55:1998;121-144.
28. Finnerty J P, Wood-Baker P, Thomson H, Holgate S T. Role of leukotrienes in exercise-induced asthma. Am Rev Respir Dis. 145:1992;617-621.
29. 4receptor antagonist ICI-204,219, Am Rev Respir Dis, 147, 1413, 18.
30. Robuschi M, Riva E, Fuccella L M, Vida E, Barnabe R, Rossi M, Gambaro G, Spagnotto S, Bianco S. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104,353). Am Rev Respir Dis. 145:1992;1285-1288.
31. Suguro O H, Majima T, Ichimura K, Hashimoto N, Koyama S, Horie T. Effect of a leukotriene antagonist, pranlukast hydrate, on exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 155:1997.
32. Spector S L. Leukotriene activity modulation in asthma. Drugs. 54:1997;369-384.
33. 4-receptor antagonist cinalukast. J Allergy Clin Immunol. 99:1997;210-215.
34. Meltzer S S, Hasday J D, Cohn J, Bleecker E R. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med. 153:1996;931-935.
35. Israel E, Dermakarian R, Rosenberg M, Sperling R, Taylor G, Rubin P, Drazen J M. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med. 323:1990;1740-1744.
36. Fischer A R, McFadden C A, Frantz R, Awni W M, Cohn J, Drazen J M, Israel E. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med. 152:1995;1203-1207.
37. 4in asthmatic patients. Eur Resp J. 11:1998;617-623.
38. Van Schoor J, Joos G F, Kips J C, Drajesk F, Carpentier P J, Pauwels R A. The effects of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects. Am J Respir Crit Care Med. 155:1997;875-880.
39. Fischer A R, Rosenberg M A, Roth M, Loper M, Jungerwirth S, Israel E. Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx1005, on asthma induced by cold dry air. Thorax. 52:1997;1074-1077.
40. 4levels following allergen and exercise challenge in bronchial asthma. Am Rev Respir Dis. 144:1991;1411-1413.
41. 4excretion in exercise-induced asthma. J Appl Physiol. 73:1991;743-748.
42. 4after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax. 52:1997;1030-1035.
43. Lazarus S C, Wong H H, Watts M J, Boushey H, Lavins B J, Minkwitz M C. The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med. 156:1997;1725-1730.
44. Fuller R W, Taylor G W, O'Connor B J. Cysteinyl leukotriene production in asthma: effects of mast cell and neurally mediated bronchoconstriction. Am Rev Respir Dis. 145:1990.
45. 2production in humans. J Appl Physiol. 71:1991;1396-1402.
46. Spencer D A, Evans J M, Green S E, Piper P J, Costello J F. Participation of the cysteinyl leukotrienes in the acute bronchoconstrictor response to inhaled platelet activating factor in man. Thorax. 46:1991;441-445.
47. 4receptor antagonist ICI 204,219. Am Rev Respir Med. 147:1993;215-217.
48. Gomez F P, Iglesia R, Roca J, Barbera J A, Chung K F, Rodriguez Roisin R. The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating factor-induced pulmonary abnormalities in mild asthma. Am J Respir Crit Care Med. 157:1998;1559-1564.
49. Dinh Xuan A T, Regnard J, Similowski T, Rey J, Marsac J, Lockhart A. Effect of SKF-104353, a leukotriene receptor antagonist, on the bronchial response to histamine in subjects with asthma: a comparative study with terfenadine. J Allergy Clin Immunol. 85:1990;865-871.
50. Kumlin M. Measurements of leukotrienes in the urine: strategies and applications. Allergy. 52:1997;124-135.
51. 4in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis. 142:1990;112-119.
52. Wenzel S E, Westcott J Y, Larsen G L. Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses. J Allergy Clin Immunol. 87:1991;540-548.
53. Chan-Yeung M, Chan H, Tse K S, Salari H, Lam S. Histamine and leukotrienes release in bronchoalveolar fluid during plicatic acid-induced bronchoconstriction. J Allergy Clin Immunol. 84:1989;762-768.
54. 4after antigen challenge and in acute asthma and allergic rhinitis. Lancet. I:1989;584-588.
55. Bel E H, Timmers M C, Dijkman J H, Stahl E G, Sterk P J. The effect of inhaled leukotriene antagonist, L-648,051, on early and late asthmatic reactions and subsequent increase in airway responsiveness in man. J Allergy Clin Immunol. 85:1990;1067-1075.
56. 4antagonist L-649,923 on the response to inhaled antigen in asthma. J Allergy Clin Immunol. 79:1987;811-816.
57. 4antagonist (L-648,051) in patients with atopic asthma. Allergy. 46:1991;266-273.
58. 4receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol. 90:1992;193-201.
59. Taylor I K, O'Shaughnessy K M, Fuller R W, Dollery C T. Effect of cysteinyl leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 337:1991;690-694.
60. Okudaira H. Challenge studies of a leukotriene receptor antagonist. Chest. 111:1997.
61. Roquet A, Dahlèn B, Kumlin M, Ihre E, Anstrén G, Binks S, Dahlén S E. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med. 155:1997;1856-1863.
62. in vivo. J Allergy Clin Immunol. 95:1995;42-51.
63. Dahlén B, Kumlin M, Ihre E, Zettreström O, Dahlén S E. Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005. Thorax. 52:1997;342-347.
64. Hamilton A L, Watson R M, Wyile G, O'Byrne P M. Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx1005. Thorax. 52:1997;342-354.
65. Hui K P, Taylor I K, Taylor G W, Rubin P, Kesterson J, Barnes N C, Barnes P J. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax. 46:1991;184-189.
66. Friedman B S, Bel E H, Buntix A, Tanaka N, Han Y H, Shingo S, Spector R, Sterk P. Oral leukotriene inhibitor (MK-886) blocks allergen induced airway responses. Am Rev Respir Dis. 147:1993;839-844.
67. 4receptor-antagonist ICI 204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Resp J. 7:1994;324-331.
68. Findlay S R, Barden J M, Easley C B, Glass M. Effect of the oral leukotriene antagonist ICI 204,219 on the antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol. 89:1992.
69. Nathan R A, Glass M, Minkwitz M C. Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest. 105:1994;483-488.
70. 4receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis. 147:1993;1431-1435.
71. Kay A B. Asthma and inflammation. J Allergy Clin Immunol. 87:1991;893-910.
72. Kane G C, Pollice M, Kim C J, Cohn J, Dworski R T, Murray J J, Sheller J R, Fish J E, Peters S P. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol. 97:1996;646-654.
73. Calhoun W J, Lavins B J, Minkwitz M C, Evans R, Gleich G J, Cohn J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation. Am J Respir Crit Care Med. 157:1998;1381-1389.
74. Sladek K, Dworski R, Soja J, Sheller J R, Nizankowska E, Oates J A, Szczeklik A. Eicosanoids in bronchoalveolar lavage fluid of asprin-intolerant patients with asthma after asprin challenge. Am J Respir Crit Care. 149:1994;940-946.
75. Szcezklik A, Sladek A, Dworski R, Nizankowska E, Soja J, Sheller J, Oates J. Bronchial asprin challenge causes specific eicosanoid response in asprin-sensitive asthmatics. Am J Respir Crit Care Med. 154:1996;1608-1614.
76. 4and histamine in asthmatics. Am Rev Respir Dis. 146:1992;96-103.
77. 4concentrations increase after aspirin challenge in aspirin-sensitive asthmatic patients. Am Rev Respir Dis. 143:1991;1025-1029.
78. 4excretion in aspirin asthma. Am J Respir Crit Care Med. 153:1996;572-575.
79. Christie P E, Smith C M, Lee T H. The potent and selective sulfidopeptide leukotriene antagonist SKF 104,353 inhibits aspirin-induced asthma. Am Rev Respir Dis. 144:1991;957-958.
80. Dahlén B, Kumlin M, Margolskee K. The leukotriene-receptor antagonist MK-0679 blocks the airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Resp J. 6:1993;1018-1026.
81. Nasser S M, Bell G S, Foster S, Spruce K E, MacMillan R, Williams A J, Lee T H, Arm J P. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax. 49:1994;749-756.
82. Israel E, Fisher A R, Rosenberg M A, Lilly C M, Callery J C, Shapiro J, Cohn J, Rubin P, Drazen M. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis. 148:1993;1447-1451.
83. 4-receptor antagonist improves pulmonary function in patients with mild asthma. Am Rev Respir Dis. 140:1989;1336-1339.
84. Am J Respir Crit Care Med. 150:1994;618-623.
85. Fish J E, Kemp J P, Lockey R F, Glass M, Hanby L A, Bonucelli C M. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clin Ther. 19:1997;675-690.
86. Spector S, Fish J E. A new approach: clinical review of zafirlukast (Accolate, ICI-204,219). Eur Resp J. 46:1997;269-273.
87. Eur Resp J. 11:1998;1232-1239.
88. Altman L C, Munk Z, Seltzer J, Noonan N, Shingo S, Zhang J, Reiss T E. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. J Allergy Clin Immunol. 102:1998;50-56.
89. Reiss T F, Chervinsky P, Dockhorn R J, Shingo S, Seidenberg B, Edwards T B. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med. 158:1998;1213-1220.
90. J Am Med Assoc. 279:1998;1181-1186.
91. Barnes N C, Pujet J C. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax. 52:1997;523-527.
92. Israel E, Rubin P, Kemp J P, Grossman J, Pierson W, Siegel S C, Tinkelman D, Murray J J, Busse W, Segal A T, Fish J, Kaiser H B, Ledford D, Wenzel S, Rosenthal R, Cohn J, Lanni C, Pearlman H, Karahalios P, Drazen M. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med. 119:1993;1059-1066.
93. Liu M C, Dubé L M, Lancaster J. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol. 98:1996;859-871.
94. Israel E, Cohn J, Dubé L, Drazen J M. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. J Am Med Assoc. 275:1996;931-936.
95. Schwartz H J, Petty T, Dubé L M, Swanson L J, Lancaster J F. A randomized controlled trial comparing zileuton with theophylline in moderate asthma. Arch Intern Med. 158:1998;141-148.
96. Wenzel S E, Trudeau J B, Kaminsky D A, Cohn J, Martin R J, Westcott J Y. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med. 152:1995;897-905.
97. 4in the assessment of nocturnal asthma. J Allergy Clin Immunol. 97:1996;735-741.
98. Eur Resp J. 10:1997;2749-2753.
99. Fisher R A, McFadden C A, Frantz R, Awni W M, Cohn J, Drazen J M, Israel E. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med. 152:1995;1203-1207.
100. Barnes N C. Are leukotrienes involved in causing bronchial hyperresponsiveness. Eur Respir J. 10:1997;2701-2703.
101. Barnes P J, Pedersen S, Busse W W. Efficacy and safety of inhaled corticosteroids. Am J Respir Crit Care Med. 157:1998;1-53.
102. Goppelt-Struebe M, Schaefer D, Habenicht A JR. Differential regulation of cyclooxygenase-2 and 5-lipoxygenase-activating protein (FLAP) expression by glucocorticoids in monocytic cells. Br J Pharmacol. 122:1997;619-624.
103. Schleimer R P, Schulman E S, MacGlashan D W, Peters S P, Hayes E C, Adams III G K, Lichtenstein L M, Adkinson N K. Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. J Clin Invest. 71:1983;1830-1835.
104. Schleimer R P, Davidson D A, Lichtenstein L M, Adkinson N F. Selective inhibition of arachidonic acid metabolite release from human lung tissue by antiinflammatory steroids. J Immunol. 136:1986;3006-3011.
105. 4by purified human neutrophils. J Pharmacol Exp Ther. 250:1989;598-605.
106. Yoss E B, Spannhake E W, Flynn J T, Fish J E, Peters S P. Arachidonic acid metabolism in normal human alveolar macrophages: stimulus specificity for mediator release and phospholipid metabolism, and pharmacological modulation in vitro and in vivo. Am J Respir Cell Mol Biol. 2:1990;69-80.
107. Balter M S, Eschenbacher W L, Peters-Golden M. Arachidonic acid metabolism in cultured alveolar macrophages from normal, atopic, and asthmatic subjects. Am Rev Respir Dis. 138:1988;1134-1142.
108. Azevedo I, De Blic J, Scheinman P, Vargaftig B B, Bachelet M. Enhanced arachidonic acid metabolism in alveolar macrophages from wheezy infants. Am J Respir Crit Care Med. 152:1995;1208-1214.
109. Sebaldt R J, Sheller J R, Oates J A, Roberts II L J, Fitzgerald G A. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci USA. 87:1990;6974-6978.
110. De Caterina R, Sicari R, Gianessi D, Paggiaro P L, Paoletti P L, Lazzerini G, Bernini W, Solito E, Parente L. Macrophage-specific eicosanoid synthesis inhibition and lipocortin-1 induction by glucocorticoids. J AppI Physiol. 75:1993;2368-2375.
111. 4biosynthesis in neutrophils from patients with rheumatoid arthritis after a single glucocorticoid dose. Biochem Pharmacol. 49:1995;243-248.
112. 4from neutrophils from asthmatic patients. Biochem Biophys Res Commun. 222:1996;759-763.
113. Dworski R, Fitzgerald G A, Oates J A, Sheller J R. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med. 149:1994;953-959.
114. 4excretion. Am Rev Respir Dis. 147:1993;1472-1476.
115. Virchow J C, Hassall S M, Summerton L, Harris A. Improved asthma control over 6 weeks with zafirlukast in patients on high dose inhaled corticosteroids. Eur Resp J. 1997.
116. 1receptor antagonist, improves asthma control in aspirin-intolerant asthmatic patients. Am J Resp Crit Care Med. 1997.
117. Yokoyama A, Kohno N, Sakai K, Hirasawa Y, Kondo K, Hiwada K. Effect of pranlukast, a leukotriene receptor antagonist, in patients with severe asthma refractory to corticosteroids. J Asthma. 35:1998;57-62.
118. Virchow J C, Kunkel G, Wiessmann K J, Dorow P, Ayres J G, Winter J H, Buhl R, Schulenburg M, Banik N, Ubrich E, Matthys H, Holgate S, Magnussen H. Multicenter trial of BAYx1005, a 5-lipoxygenase activating protein (FLAP) inhibitor in steroid-dependent asthma. Am J Respir Crit Care Med. 155:1997.
119. Chapman K R, Friedman B S, Shingo S, Heyse J, Reiss T, Spector R. The efficacy of an oral inhibitor of leukotriene synthesis (MK-0591) in asthmatics treated with inhaled steroids. Am Rev Respir Dis. 1994.
120. Dahlén B, Nizankowska E, Szczeklik A, Zetterström O, Bochenek G, Kumlin M, Mastalerz L, Pinis G, Swanson U, Boodhoo T I, Wright S, Dubé L M, Dahlén S E. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med. 157:1998;1187-1194.
121. Tamaoki J, Kondo M, Sakai N, Nakata J, Takemura H, Nagai A, Takizawa T, Konno K. Leukotriene antagonists prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med. 155:1997;1235-1240.
122. Leff J A, Israel E, Noonan M J, Finn A F, Godard P, Lofdahl C G, Friedman B S, Connors L, Weinland D E, Reiss T F, Kundu S. Montelukast (MK-0476) allows tapering of inhaled corticosteroids in asthmatics patients while maintaining clinical stability. Am J Respir Crit Care Med. 1997.
123. Björck T, Dahlén S E. Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissue from asthmatic and non asthmatic subjects. Pulm Pharmacol. 6:1993;87-96.
124. Reicin A S, Weinstein S F, White R, Fineman S M, Nguyen H, Geissler L, Peszek I, Seidenberg B. Montelukast+Loratadine compared to alone provides additional benefit in the treatment of chronic asthma. Am J Respir Crit Care Med. 157:1998.
125. In K H, Asano K, Beier D, Grobholz J, Finn P W, Silverman E K, Silverman E S, Collins T, Fischer A R, Keith T P, Serino K, Kim S W, De Sanctis G T, Yandava C, Pillari A, Rubin P, Kemp J, Israel E, Busse W, Ledford D, Murray J J, Segal A, Tinkelman D, Drazen J. Naturally occurring mutatins in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reported gene transcription. J Clin Invest. 99:1997;1130-1137.
126. 4synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet. 350:1997;1599-1600.
127. Drazen J M, Yandava C, Pillari A, In K H, Swanson L, Dydo M, Szczerbak N, Dube L, Zileuton Study Group L. Relationship between 5-LO gene promoter mutations and lung function responses to 5-LO inhibition. Am J Respir Crit Care Med. 155:1997.
128. Tashkin D P, Nathan R A, Howland N C, Minkwitz M C, Bonucelli C M. Efficacy of zafirlukast (Accolate): exploratory subset data from three 13-week multicenter trials. Am J Respir Crit Care Med. 155:1997.
129. Weschler M E, Garpestad E, Flier S R, Kocher O, Weiland D A, Polito A J, Klinek M M, Bigby T D, Wong G A, Helmers R A, Drazen M. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. J Am Med Assoc. 279:1998;455-457.
130. Knoell D L, Lucas J, Allen J N. Churg-Strauss syndrome associated with zafirlukast. Chest. 14:1998;332-334.
131. Formulary. 32:1997;894-895.
132. Package insert J N. Zyflo filintab. 1996;Abbott Laboratories, IL:
133. SCRIP. 2017:1995;29-31.
134. Horwitz R J, McGill K A, Busse W W. The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med. 157:1998;1363-1371.
135. Kelloway J S, Wyatt R A, Adlis S A. Comparison of patient's compliance with prescribed oral and inhaled asthma medications. Arch Intern Med. 154:1994;1349-1352.
136. Lee T, Grossman J, Swanson L J, Dube L, Nabulsi A, Rountree L, Hippensteel R. Safety of zileuton, 1200 mg bid, controlled release and 600 mg qid, immediate release in patients with moderate asthma. Am J Respir Crit Care Med. 157:1998.
137. Boulet L P. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest. 113:1998;587-592.
138. Wenzel S E, Trudeau J B, Kaminsky D A, Cohn J, Martin R J, Westcott J Y. Effect of 5-lipoxygenase inhibitor on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med. 152:1995;897-905.
139. 4and histamine-induced cutaneous vascular reactions in man. J Allergy Clin Immunol. 87:1991;93-98.
140. 4receptor antagonist devoid of peroxisomal enzyme induction. Bioorg Med Chem Lett. 5:1995;283-288.
141. 4in guinea-pigs. Clin Exp Allergy. 24:1994;960-968.
142. 4antagonist compound LY171883 on fisher 344 rats and rhesus monkeys. Fund Appl Toxicol. 14:1990;123-130.
143. Foxworthy P S, Perry D N, Hoover D M, Eacho P I. Changes in hepatic lipid metabolism associated with lipid accumulation and its reversal in rats given the peroxisome proliferator LY17883. Fund Appl Toxicol. 106:1990;375-383.